This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About PPV

About PPV

Updated on 18/04/2018

VACCINES

Licensed indication1

PNEUMOCOCCAL POLYSACCHARIDE VACCINE is recommended for active immunisation against disease caused by the pneumococcal serotypes included in the vaccine. The vaccine is recommended for individuals 2 years of age or older in whom there is an increased risk of morbidity and mortality from pneumococcal disease. The specific at risk categories of persons to be immunised are to be determined on the basis of official recommendations.

The vaccine is not effective for the prevention of acute otitis media, sinusitis and other common upper respiratory tract infections.

  • PPV can help protect patients at increased risk of pneumococcal disease1
  • PPV is significantly protective against pneumococcal pneumonia and invasive pneumococcal disease (IPD) in adult patients1
  • PPV is the only pneumococcal vaccine indicated against 23 serotypes in the UK, including 11 unique serotypes1
  • The 23 serotypes included in PPV account for about 96% of the pneumococcal isolates that cause serious infection in the UK2

PCV13=13-valent PNEUMOCOCCAL CONJUGATE VACCINE

PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV) is an effective preventative measure for a number of at-risk individuals, helping to protect against pneumococcal pneumonia and invasive pneumococcal disease (such as septicaemia and meningitis) and their potential complications. The Department of Health has initiated a national immunisation programme in the UK, offering eligible individuals immunisation on the NHS.2

Often associated with pneumonia, pneumococcal infections are more widespread and can include inner ear infections, sinus infections, meningitis or sepsis.2
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-valent, adsorbed) (PCV) is used in the childhood vaccination schedule and PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV) is used in at risk patient groups and the over 65’s national immunisation programme. PCV followed by PPV is used for severely immunocompromised individuals.2
Posology/dosing1
Contraindications1
Interactions with other medicinal products1
Adverse events1

References

  1. PNEUMOCOCCAL POLYSACCHARIDE VACCINE Summary of Product Characteristics.
  2. Department of Health Green Book Chapter 25. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/674074/GB_Chapter_25_Pneumococcal_V7_0.pdf Accessed March 2018.
  3. PREVENAR 13 Summary of Product Characteristics.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

VACC-1250419-0000 | Date of Preparation: April 2018